1文献来源Xu B,Zhang Q,Zhang P,et al.Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer:a randomized,phase 3 trial[J].Nat Med,2021,27(11):1904-1909.2证据水平1b。
1文献来源Prat A,Saura C,Pascual T,et al.Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor⁃positive,HER2⁃negative,luminal B breast cancer(CORALLEEN):an open⁃label,multicentre,...1文献来源Prat A,Saura C,Pascual T,et al.Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor⁃positive,HER2⁃negative,luminal B breast cancer(CORALLEEN):an open⁃label,multicentre,randomised,phase 2 trial[J].Lancet Oncol,2020,21(1):33-43.展开更多
1文献来源Lu Y-S, Mahidin EIBM, Azim H, et al.Abstract GS1-10:Primary results from the randomized phaseⅡRIGHT Choice trial of premenopausal patients with aggressive HR+/HER2-advanced breast cancer treated with ribocic...1文献来源Lu Y-S, Mahidin EIBM, Azim H, et al.Abstract GS1-10:Primary results from the randomized phaseⅡRIGHT Choice trial of premenopausal patients with aggressive HR+/HER2-advanced breast cancer treated with ribociclib+endocrine therapy vs physician’s choice combination chemotherapy[J].Cancer Res,2023,83(5S):GS1-10.展开更多
1文献来源Im SA,Lu YS,Bardia A,et al.Overall survival with ribociclib plus endocrine therapy in breast cancer[J].N Engl J Med,2019,381(4):307-316.2证据水平1b。3背景年轻乳腺癌(<50岁)患者在所有乳腺癌患者中占比很高,且...1文献来源Im SA,Lu YS,Bardia A,et al.Overall survival with ribociclib plus endocrine therapy in breast cancer[J].N Engl J Med,2019,381(4):307-316.2证据水平1b。3背景年轻乳腺癌(<50岁)患者在所有乳腺癌患者中占比很高,且这部分患者中大约三分之二是激素受体(hormone receptor,HR)阳性(定义为雌激素或孕激素受体表达,或两者都表达).展开更多
1文献来源Johnston SRD,Harbeck N,Hegg R,et al.monarchE Committee Members and Investigators.Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+,HER2-,node-positive,high-risk,early breast cancer...1文献来源Johnston SRD,Harbeck N,Hegg R,et al.monarchE Committee Members and Investigators.Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+,HER2-,node-positive,high-risk,early breast cancer(monarchE)[J].J Clin Oncol,2020,38(34):3987-3998.展开更多
文摘1文献来源Xu B,Zhang Q,Zhang P,et al.Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer:a randomized,phase 3 trial[J].Nat Med,2021,27(11):1904-1909.2证据水平1b。
文摘1文献来源Prat A,Saura C,Pascual T,et al.Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor⁃positive,HER2⁃negative,luminal B breast cancer(CORALLEEN):an open⁃label,multicentre,randomised,phase 2 trial[J].Lancet Oncol,2020,21(1):33-43.
文摘1文献来源Lu Y-S, Mahidin EIBM, Azim H, et al.Abstract GS1-10:Primary results from the randomized phaseⅡRIGHT Choice trial of premenopausal patients with aggressive HR+/HER2-advanced breast cancer treated with ribociclib+endocrine therapy vs physician’s choice combination chemotherapy[J].Cancer Res,2023,83(5S):GS1-10.
文摘1文献来源Im SA,Lu YS,Bardia A,et al.Overall survival with ribociclib plus endocrine therapy in breast cancer[J].N Engl J Med,2019,381(4):307-316.2证据水平1b。3背景年轻乳腺癌(<50岁)患者在所有乳腺癌患者中占比很高,且这部分患者中大约三分之二是激素受体(hormone receptor,HR)阳性(定义为雌激素或孕激素受体表达,或两者都表达).
文摘1文献来源Johnston SRD,Harbeck N,Hegg R,et al.monarchE Committee Members and Investigators.Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+,HER2-,node-positive,high-risk,early breast cancer(monarchE)[J].J Clin Oncol,2020,38(34):3987-3998.
